BERGEM·HEALTH
Free consultation
Home › Treatments › Oncology
SPECIALITY · ONCOLOGY

Oncology in Türkiye — tumour board in 72 hours, immunotherapy and proton therapy.

Multidisciplinary plan from Memorial, Liv Hospital and Akdeniz professors. Direct access, no agency markup.

What you get
  • Multidisciplinary tumor board decision within 72 hours
  • Immunotherapy, targeted therapy, proton therapy programmes
  • Direct access to professors at Memorial, Liv and Akdeniz
  • English-speaking coordinator and translator throughout
6 hospitals · 12 oncology professors · NCCN/ESMO protocols
New: CAR T-cell therapy at our partner Akdeniz University (Antalya). Türkiye's first university-based CAR-T and cellular-therapies production centre has completed its licensing and is preparing for its first patients — established CAR T for blood cancers, with clinical-trial programmes for some solid tumours now concluding. Read the complete CAR T-cell therapy guide →   See the announcement
SECOND OPINION ONLINE

Tumor board second opinion — within 72 hours, free

Send your recent imaging, biopsy, and treatment history — a 5-specialist tumor board returns a written plan in 72 hours, free of charge.

01
Upload your discharge summary
Discharge summaries, CT/MRI discs (DICOM), histology slides if available. Up to 200 MB.
02
Coordinator reviews
Selects 2–3 professors matched to your diagnosis and stage. Sends them your records.
03
Video consultation
The professor responds online — review of histology, protocol, travel plan if needed.
What to send
  • Discharge summaries from inpatient / outpatient care
  • CT or MRI — original DICOM discs
  • Histology report (if available)
  • Slides or blocks for review (optional)
  • Current therapy list
Request a second opinion
Free. Confidential. Anna Moroz reads every request personally.
11 PROCEDURES

What we treat in oncology

Full scope of solid tumors and hematologic malignancies, multidisciplinary tumor board within 72 hours.

TREATMENT METHODS

Treatment methods in oncology

NCCN/ESMO protocols, immunotherapy, targeted therapy guided by NGS, modern radiation including proton.

Multidisciplinary tumor board (MDT)
Surgeon + medical oncologist + radiation oncologist + radiologist + pathologist convene per case.
6 clinics
Immunotherapy (checkpoint inhibitors)
Pembrolizumab, nivolumab, atezolizumab, ipilimumab. PD-L1/MSI guided.
5 clinics
Targeted therapy (NGS-guided)
Next-generation sequencing to find actionable mutations; FDA/EMA-approved targeted agents.
4 clinics
Proton therapy
Available in selected partner centres for pediatric, brain and base-of-skull tumors.
1 clinic
SBRT / SRS / VMAT
Stereotactic body radiotherapy, stereotactic radiosurgery, volumetric modulated arc therapy.
5 clinics
Surgical oncology (organ-sparing)
Da Vinci robotic surgery, laparoscopic resections, breast-conserving operations.
6 clinics
CAR-T & advanced cell therapy
CAR-T cell therapy for relapsed/refractory lymphomas in select centres. Now available at our partner Akdeniz University in Antalya — Türkiye's first university-based CAR-T production centre.
1 clinic
Chemotherapy (cytotoxic + targeted)
Day-hospital infusion centre, NCCN/ESMO regimens.
6 clinics
ONCOLOGY · TEAM

Professors you get direct access to

Department heads at JCI hospitals in Türkiye. Direct contact, no middlemen.

Prof. Dr. Mustafa Özdoğan
Professor of Medical Oncology
Memorial Göztepe Hospital, Istanbul
Prof. Dr. Aylin Fidan Korcum Şahin, MD
Professor of Radiation Oncology, Department Chair
Akdeniz University Hospital
Prof. Dr. Nasuh Utku Doğan
Professor of gynaecological oncology, private practice
Private practice, Antalya
Prof. Dr. Ömer Kutlu
Professor and Head of the Andrology Unit, Department of Urology
Akdeniz University Hospital, Antalya
Doç. Dr. Hakan Çakın
Associate professor at the Department of Neurosurgery
Akdeniz University Hospital, Antalya
Prof. Dr. Mustafa Karaca
Professor at the Department of Medical Oncology
Akdeniz University Faculty of Medicine, Antalya
Prof. Dr. Erdal Karaöz
Director of the Centre for Regenerative Medicine and Stem Cells
Liv Hospital Ulus, Istanbul
Prof. Dr. Muhittin Yaprak
Professor at the Department of General Surgery
Akdeniz University Hospital, Antalya
Prof. Dr. Koray Acarlı
Professor at the Department of General and Hepatopancreatobiliary (HPB) Surgery
Liv Hospital Ulus, Istanbul
Prof. Dr. Meral Günaldı
Professor of Medical Oncology
Liv Hospital Ulus, Istanbul
Prof. Dr. Selen Doğan
Professor at the Department of Obstetrics & Gynaecology, Gynaecologic Oncology Unit
Akdeniz University Hospital, Antalya
Prof. Dr. Cumhur Arıcı
Professor at the Department of General Surgery; Head of the Endocrine Surgery Unit
Akdeniz University Hospital, Antalya
Prof. Dr. Alpay Sarper, MD
Head of Thoracic Surgery
Akdeniz University Hospital
Prof. Dr. Ali Yeginsu
Professor of Thoracic Surgery
Akdeniz University Hospital
Prof. Dr. Levent Dertsiz
Professor of Thoracic Surgery
Akdeniz University Hospital
ME
Prof. Dr. Makbule Ergin
Professor of Thoracic Surgery
Akdeniz University Hospital
Prof. Dr. İsmail Hakkı Sarpün, PhD
Professor of Physics (Nuclear & Medical Physics)
Akdeniz University, Faculty of Science
Prof. Dr. Mine Genc Ozay
Professor of Radiation Oncology
Akdeniz University Hospital
Assoc. Prof. Hakan Keskin, MD
Associate Professor of Thoracic Surgery
Akdeniz University Hospital
Prof. Dr. Timur Koca
Professor of Radiation Oncology
Akdeniz University Hospital
Prof. Dr. Sema Sezgin Goksu
Professor of Medical Oncology
Akdeniz University Hospital
Assoc. Prof. MD. Ozan Balakan
Associate Professor of Medical Oncology
İSÜ Liv Hospital Bahçeşehir
Assoc. Prof. Dr. Erkan Kayıkçıoğlu, MD
Associate Professor of Medical Oncology
İSÜ Liv Hospital Bahçeşehir
Assoc. Prof. Dr. Akın Yıldızhan, MD
Associate Professor of Thoracic Surgery
İSÜ Liv Hospital Bahçeşehir
CLINICS

Clinics where treatment takes place

JCI-accredited hospitals with specialised departments and end-to-end support.

JCI GOLD SEAL
Akdeniz University Hospital

The largest university hospital in Türkiye’s Mediterranean region. 218,348 m² of floor area, 33 specialised departments, 1,267 beds, 8 buildings.…

Learn more about the clinic
JCI GOLD SEAL
İSÜ Liv Hospital Bahçeşehir

A multidisciplinary Liv Hospital campus on the European side of Istanbul. Opened in December 2016. 60+ departments: cardiology, neurosurgery, oncology,…

Learn more about the clinic
JCI GOLD SEAL
Liv Hospital Vadistanbul

The sixth hospital of the Liv group. Robotic surgery with da Vinci SP Single Port, 3 Tesla MRI, PET/CT, Versa-HD…

Learn more about the clinic
JCI GOLD SEAL
Liv Hospital Ulus

The flagship hospital of the Liv Hospital group in the upscale Ulus district. JCI accreditation and the first SRC certificate…

Learn more about the clinic
JCI GOLD SEAL
Memorial Bahçelievler Hospital

The oncology centre of the Memorial network. 320 beds, 15 operating theatres (one hybrid), 49 ICU beds. Full cycle —…

Learn more about the clinic
JCI GOLD SEAL
Memorial Antalya Hospital

Memorial Antalya is part of Türkiye’s first JCI-accredited medical group. 114 inpatient beds plus 18 observation beds, 4 ICUs (general,…

Learn more about the clinic
DIAGNOSTICS

Oncology diagnostics

PET-CT, multiparametric MRI, NGS, liquid biopsy and expert pathology — typically completed within 5–10 days.

PET-CT (FDG, PSMA, Ga-68 DOTATATE)
Whole-body staging and restaging with multiple radiotracers.
1 day
MRI 3T (with diffusion + spectroscopy)
Brain, breast, prostate (multiparametric), liver, pelvis.
1 day
Biopsy & molecular pathology
IHC + FISH + MSI status + tumor grading by experienced pathologists.
3–5 days
NGS panel (Next-Gen Sequencing)
500+ gene panel to find actionable mutations.
10–14 days
EBUS-TBNA / EUS-FNA
Endoscopic ultrasound-guided sampling of mediastinal/abdominal lesions.
1 hour
Liquid biopsy (ctDNA)
Blood-based monitoring of tumor DNA for treatment response.
7–10 days
Tumor markers panel
CA 15-3, CA 19-9, CEA, AFP, PSA, CA 125 with quality control.
1 day
PRICE SNAPSHOT

Oncology pricing — Türkiye vs EU/USA

Final cost is determined by the medical board after reviewing documents. Prices are indicative.

Procedure Türkiye EU / USA Savings
Tumor board second opinion Free $1 500 – 3 500 −100%
PET-CT (whole body) $800 – 1 400 $3 500 – 7 000 −75%
NGS panel (500+ genes) $1 800 – 3 500 $8 000 – 15 000 −75%
Immunotherapy (3 cycles pembrolizumab) $6 000 – 10 000 $30 000 – 60 000 −80%
Proton therapy course $45 000 – 75 000 $120 000 – 250 000 −65%
Breast cancer surgery + reconstruction $12 000 – 22 000 $40 000 – 100 000 −75%
CAR-T cell therapy $120 000 – 180 000 $400 000 – 600 000 −65%
Chemotherapy cycle $800 – 2 000 $5 000 – 12 000 −80%
The information on this page is for reference only and does not constitute a medical opinion.
Request a precise quote for my case
QUESTIONS

Frequently asked about Oncology

Tumor board decision — what is in it?
A written treatment plan from 5 specialists (surgeon, medical oncologist, radiation oncologist, radiologist, pathologist) within 72 hours. Includes staging confirmation, recommended sequence (surgery first vs. neoadjuvant chemo), specific drug regimens, and expected timeline.
Immunotherapy — am I eligible?
Depends on tumor type, PD-L1 status, MSI status, and prior treatments. Most lung, melanoma, kidney, bladder and many GI cancers have approved immunotherapy options. We review your biopsy and run PD-L1 IHC if not already done.
Proton therapy — when is it preferred over IMRT?
Pediatric cancers, base-of-skull tumors, ocular melanoma, and selected re-irradiations. Reduces dose to surrounding healthy tissue. Decision made by the radiation oncology team based on dosimetry simulation.
Second opinion — what to send?
Recent imaging (CT, MRI, PET-CT), pathology slides or report, prior treatment history, current medications, and any genetic/molecular tests. We arrange remote review and return a written second opinion within 72 hours.
Am I eligible for CAR-T cell therapy and is it available in Turkey?
CAR-T (axicabtagene, tisagenlecleucel, brexucabtagene) is indicated for relapsed/refractory DLBCL after 2 lines, multiple myeloma after 4 lines, and B-ALL up to age 25. Several Istanbul and Ankara JCI centers are accredited apheresis and infusion sites, with cells manufactured abroad and total turnaround of 4-6 weeks. CRS and ICANS are managed in dedicated cellular therapy units; complete response rates reach 50-80% depending on disease.
When is liquid biopsy (ctDNA) ordered and what does it add to tissue biopsy?
Liquid biopsy is used when tissue is insufficient, the tumor is inaccessible, or rapid genotyping is needed at progression, particularly in NSCLC, colorectal and breast cancer. It detects actionable mutations (EGFR, KRAS, BRAF, ESR1) with sensitivity 70-85% and turnaround of 7-10 days versus 14-21 for tissue NGS. ctDNA is also used for minimal residual disease monitoring after curative surgery.
How does NGS-guided targeted therapy change my treatment plan?
Comprehensive NGS (500+ genes) identifies actionable alterations in roughly 40% of solid tumors — KRAS G12C (sotorasib, adagrasib), EGFR exon 19/L858R (osimertinib), ALK/ROS1 (lorlatinib), BRAF V600E (dabrafenib-trametinib, encorafenib), and HER2-low (trastuzumab deruxtecan). Results are reviewed at the molecular tumor board within 10-14 days, and FDA/EMA-approved targeted agents are matched before chemotherapy where possible.
REQUEST

Tell me about your case — I’ll read it personally.

Fill in the short form on the consultation page — diagnosis, preferred timing, attached records. We assemble a tumour board for your case and reply within 4 hours.

Open the consultation form
  • Reply within 4 hours during business hours
  • Confidentiality guaranteed
  • Coordinator-translator inside the doctor’s office
  • Tumour board of 2–3 professors within 72 hours